Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 25Sarcoma 4Carcinoma, Neuroendocrine 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Breast Neoplasms 3Thyroid Neoplasms 2Stomach Neoplasms 2Pheochromocytoma 2Paraganglioma 2Neoplasms by Site 2Neoplasms by Histologic Type 2Melanoma 2Liver Neoplasms 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Digestive System Neoplasms 2Colonic Neoplasms 2Colonic Diseases 2Carcinoma, Renal Cell 2Carcinoid Tumor 2Adenoma, Islet Cell 2Adenocarcinoma 2Vulvar Neoplasms 1Urogenital Neoplasms 1

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Digestive System Neuroendocrine Tumor G1 × NET × 30 days × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡